AKT1 is altered in 1.65% of cervical carcinoma patients [2].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK is altered in 2.42% of cervical carcinoma patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ARID1A is altered in 9.79% of cervical carcinoma patients [2].

ARID1A is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ARID1A status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

ATM is altered in 5.29% of cervical carcinoma patients [2].

ATM is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATM status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

ATR is altered in 3.14% of cervical carcinoma patients [2].

ATR is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATR status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

ATRX is altered in 5.39% of cervical carcinoma patients [2].

ATRX is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ATRX status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

BARD1 is altered in 0.92% of cervical carcinoma patients [2].

BARD1 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BARD1 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

BIRC2 is altered in 0.42% of cervical carcinoma patients [2].

BIRC2 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC2 status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BIRC3 is altered in 1.99% of cervical carcinoma patients [2].

BIRC3 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRAF is altered in 1.64% of cervical carcinoma patients [2].

BRAF is an inclusion eligibility criterion in 2 clinical trials for cervical carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and cervical carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

BRCA1 is altered in 3.19% of cervical carcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA1 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

BRCA2 is altered in 2.89% of cervical carcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA2 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

BRIP1 is altered in 2.53% of cervical carcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRIP1 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

C11orf30 is altered in 1.33% of cervical carcinoma patients [2].

C11orf30 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain C11orf30 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

CARD11 is altered in 2.29% of cervical carcinoma patients [2].

CARD11 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CCND1 is altered in 1.96% of cervical carcinoma patients [2].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCNE1 is altered in 1.26% of cervical carcinoma patients [2].

CCNE1 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

CD79A is altered in 0.36% of cervical carcinoma patients [2].

CD79A is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD79A status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD79B is altered in 0.79% of cervical carcinoma patients [2].

CD79B is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CDK12 is altered in 2.36% of cervical carcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CDK12 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

CDK4 is altered in 0.5% of cervical carcinoma patients [2].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 is altered in 0.77% of cervical carcinoma patients [2].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN2A is altered in 3.54% of cervical carcinoma patients [2].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK1 is altered in 0.62% of cervical carcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CHEK1 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

CHEK2 is altered in 1.01% of cervical carcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CHEK2 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

CSF1R is altered in 0.72% of cervical carcinoma patients [2].

CSF1R is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR is altered in 1.28% of cervical carcinoma patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EPCAM is altered in 0.33% of cervical carcinoma patients [2].

EPCAM is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is altered in 9.09% of cervical carcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [3].

ERBB3 is altered in 5.37% of cervical carcinoma patients [2].

ERBB3 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC2 is altered in 0.76% of cervical carcinoma patients [2].

ERCC2 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERCC2 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

ERCC3 is altered in 1.37% of cervical carcinoma patients [2].

ERCC3 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERCC3 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

ERCC4 is altered in 0.8% of cervical carcinoma patients [2].

ERCC4 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERCC4 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

ERCC5 is altered in 1.39% of cervical carcinoma patients [2].

ERCC5 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERCC5 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

ERCC6 is altered in 0.97% of cervical carcinoma patients [2].

ERCC6 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERCC6 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

EXO1 is altered in 1.96% of cervical carcinoma patients [2].

EXO1 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCA is altered in 1.96% of cervical carcinoma patients [2].

FANCA is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FANCA status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FANCB is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCB status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FANCC is altered in 1.01% of cervical carcinoma patients [2].

FANCC is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCC status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FANCD2 is altered in 3.41% of cervical carcinoma patients [2].

FANCD2 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCD2 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FANCE is altered in 1.82% of cervical carcinoma patients [2].

FANCE is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCE status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FANCF is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCF status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FANCG is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCG status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FANCI is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCI status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FANCL is altered in 3.74% of cervical carcinoma patients [2].

FANCL is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCL status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FANCM is altered in 7.89% of cervical carcinoma patients [2].

FANCM is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FANCM status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FGFR1 is altered in 2.55% of cervical carcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 is altered in 1.7% of cervical carcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR3 is altered in 2.47% of cervical carcinoma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 is altered in 2.8% of cervical carcinoma patients [2].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is altered in 1.52% of cervical carcinoma patients [2].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 is altered in 2.29% of cervical carcinoma patients [2].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HDAC1 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HDAC1 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HDAC2 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

KDR is altered in 2.3% of cervical carcinoma patients [2].

KDR is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is altered in 1.55% of cervical carcinoma patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MDM2 is altered in 1.01% of cervical carcinoma patients [2].

MDM2 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MDM2 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

MDM4 is altered in 0.76% of cervical carcinoma patients [2].

MDM4 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MDM4 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

MET is altered in 1.89% of cervical carcinoma patients [2].

MET is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MLF1 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

MLH1 is altered in 3.18% of cervical carcinoma patients [2].

MLH1 is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MLH1 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

MLH3 is altered in 3.16% of cervical carcinoma patients [2].

MLH3 is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MLH3 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

MRE11A is altered in 0.59% of cervical carcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MRE11A status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

MSH2 is altered in 1.21% of cervical carcinoma patients [2].

MSH2 is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MSH2 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

MSH3 is altered in 1.04% of cervical carcinoma patients [2].

MSH3 is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MSH3 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

MSH6 is altered in 2.15% of cervical carcinoma patients [2].

MSH6 is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MSH6 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

MST1R is altered in 0.9% of cervical carcinoma patients [2].

MST1R is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MST1R status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MTOR is altered in 1.83% of cervical carcinoma patients [2].

MTOR is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MUTYH is altered in 0.75% of cervical carcinoma patients [2].

MUTYH is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MUTYH status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

MYC is altered in 3.77% of cervical carcinoma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

NBN is altered in 1.76% of cervical carcinoma patients [2].

NBN is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain NBN status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

NFKBIA is altered in 1.38% of cervical carcinoma patients [2].

NFKBIA is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NFKBIA status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NPM1 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

NRG1 is altered in 0.77% of cervical carcinoma patients [2].

NRG1 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRG1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK1 is altered in 1.26% of cervical carcinoma patients [2].

NTRK1 is an inclusion eligibility criterion in 2 clinical trials for cervical carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK1 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

NTRK2 is altered in 0.51% of cervical carcinoma patients [2].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK3 is altered in 1.47% of cervical carcinoma patients [2].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PALB2 is altered in 0.48% of cervical carcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PALB2 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

PARP1 is altered in 0.75% of cervical carcinoma patients [2].

PARP1 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PARP1 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PARP2 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

PCNA is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is altered in 1.57% of cervical carcinoma patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB is altered in 1.26% of cervical carcinoma patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3CA is altered in 27.69% of cervical carcinoma patients [2].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS1 is altered in 1.57% of cervical carcinoma patients [2].

PMS1 is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PMS1 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

PMS2 is altered in 0.52% of cervical carcinoma patients [2].

PMS2 is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PMS2 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

POLD1 is altered in 2.89% of cervical carcinoma patients [2].

POLD1 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE is altered in 3.18% of cervical carcinoma patients [2].

POLE is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain POLE status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

PPP2R1A is altered in 1.55% of cervical carcinoma patients [2].

PPP2R1A is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PPP2R1A status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

PPP2R2A is altered in 3.12% of cervical carcinoma patients [2].

PPP2R2A is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PPP2R2A status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

PTEN is altered in 7.3% of cervical carcinoma patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD50 is altered in 2.62% of cervical carcinoma patients [2].

RAD50 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD50 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

RAD51 is altered in 0.52% of cervical carcinoma patients [2].

RAD51 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

RAD51B is altered in 0.65% of cervical carcinoma patients [2].

RAD51B is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51B status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

RAD51C is altered in 0.96% of cervical carcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain RAD51C status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

RAD51D is altered in 0.97% of cervical carcinoma patients [2].

RAD51D is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51D status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

RAD54L is altered in 1.27% of cervical carcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD54L status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

RAF1 is altered in 0.75% of cervical carcinoma patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RB1 is altered in 4.48% of cervical carcinoma patients [2].

RB1 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

RET is altered in 1.52% of cervical carcinoma patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC1 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC2 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC3 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC4 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC5 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ROS1 is altered in 3.11% of cervical carcinoma patients [2].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA1 is altered in 1.96% of cervical carcinoma patients [2].

RPA1 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA2 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA3 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA4 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SLX4 is altered in 0.86% of cervical carcinoma patients [2].

SLX4 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain SLX4 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

SMARCB1 is altered in 0.62% of cervical carcinoma patients [2].

SMARCB1 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain SMARCB1 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

SSBP1 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

STAG2 is altered in 2.58% of cervical carcinoma patients [2].

STAG2 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain STAG2 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

STK11 is altered in 8.21% of cervical carcinoma patients [2].

STK11 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain STK11 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

TNFAIP3 is altered in 0.49% of cervical carcinoma patients [2].

TNFAIP3 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TNFAIP3 status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TP53 is altered in 14.75% of cervical carcinoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

TSC1 is altered in 1.83% of cervical carcinoma patients [2].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC2 is altered in 3.36% of cervical carcinoma patients [2].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VHL is altered in 0.59% of cervical carcinoma patients [2].

VHL is an inclusion eligibility criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

XRCC1 is altered in 2.63% of cervical carcinoma patients [2].

XRCC1 is an inclusion eligibility criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain XRCC1 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].